While the connection between inflammation and depression is still under investigation, our data highlight a new translational control pathway, which may underlie the chronic antidepressant action of SSRIs and could be exploited to design novel antidepressants by boosting eIF4E phosphorylation (Fig. 7C). The gene discussed is EIF4E; the disease is depressive symptom measurement.